ATE500849T1 - Antikoagulans/antithrombose-dual-hemmer mit einem biotin-label - Google Patents
Antikoagulans/antithrombose-dual-hemmer mit einem biotin-labelInfo
- Publication number
- ATE500849T1 ATE500849T1 AT06807029T AT06807029T ATE500849T1 AT E500849 T1 ATE500849 T1 AT E500849T1 AT 06807029 T AT06807029 T AT 06807029T AT 06807029 T AT06807029 T AT 06807029T AT E500849 T1 ATE500849 T1 AT E500849T1
- Authority
- AT
- Austria
- Prior art keywords
- oligosaccharide
- residue
- gpiib
- spacer
- compound
- Prior art date
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title abstract 6
- 230000002785 anti-thrombosis Effects 0.000 title abstract 3
- 229960002685 biotin Drugs 0.000 title abstract 3
- 235000020958 biotin Nutrition 0.000 title abstract 3
- 239000011616 biotin Substances 0.000 title abstract 3
- 239000003146 anticoagulant agent Substances 0.000 title 1
- 229940127219 anticoagulant drug Drugs 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000002482 oligosaccharides Chemical class 0.000 abstract 4
- 239000005557 antagonist Substances 0.000 abstract 2
- 229920001542 oligosaccharide Polymers 0.000 abstract 2
- 108090001008 Avidin Proteins 0.000 abstract 1
- 102000008946 Fibrinogen Human genes 0.000 abstract 1
- 108010049003 Fibrinogen Proteins 0.000 abstract 1
- 108010090804 Streptavidin Proteins 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 230000001858 anti-Xa Effects 0.000 abstract 1
- 150000007942 carboxylates Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940012952 fibrinogen Drugs 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001483 monosaccharide substituent group Chemical group 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05109403 | 2005-10-10 | ||
| EP05109962 | 2005-10-25 | ||
| PCT/EP2006/067127 WO2007042469A2 (en) | 2005-10-10 | 2006-10-06 | Anticoagulant antithrombotic dual inhibitors comprising a biotin label |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE500849T1 true ATE500849T1 (de) | 2011-03-15 |
Family
ID=37451080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06807029T ATE500849T1 (de) | 2005-10-10 | 2006-10-06 | Antikoagulans/antithrombose-dual-hemmer mit einem biotin-label |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1991271B1 (de) |
| JP (1) | JP5060486B2 (de) |
| KR (1) | KR20080055960A (de) |
| AT (1) | ATE500849T1 (de) |
| AU (1) | AU2006301331B2 (de) |
| BR (1) | BRPI0617215A2 (de) |
| CA (1) | CA2624588C (de) |
| DE (1) | DE602006020634D1 (de) |
| EC (1) | ECSP088443A (de) |
| HR (1) | HRP20110331T1 (de) |
| IL (1) | IL190523A0 (de) |
| MY (1) | MY145269A (de) |
| NO (1) | NO20081619L (de) |
| NZ (1) | NZ567221A (de) |
| PL (1) | PL1991271T3 (de) |
| RU (1) | RU2434876C2 (de) |
| WO (1) | WO2007042469A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201006479A (en) * | 2008-07-18 | 2010-02-16 | Sanofi Aventis | Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment |
| EP2145624A1 (de) * | 2008-07-18 | 2010-01-20 | Sanofi-Aventis | Verwendung von Idrabiotaparinux zur Senkung der Blutungsinzidenz bei einer Thrombosebehandlung |
| EP2233143A1 (de) * | 2009-03-24 | 2010-09-29 | Sanofi-Aventis | Verwendung von Idrabiotaparinux zur Senkung der Blutungsinzidenz bei einer Thrombosebehandlung |
| AU2010332797B2 (en) | 2009-12-18 | 2015-05-28 | Catalent Pharma Solutions Gmbh | Pharmaceutical oral dosage form containing a synthetic oligosaccharide |
| JP2013537181A (ja) * | 2010-09-10 | 2013-09-30 | サノフイ | 抗血栓活性及び改善された代謝安定性を有するビオチン化多糖類 |
| WO2012172104A1 (en) * | 2011-06-17 | 2012-12-20 | Endotis Pharma | Synthetic pentasaccharides having short half-life and high activity |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6217869B1 (en) * | 1992-06-09 | 2001-04-17 | Neorx Corporation | Pretargeting methods and compounds |
| FR2751334B1 (fr) * | 1996-07-19 | 1998-10-16 | Sanofi Sa | Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant |
| WO1999065934A1 (en) * | 1998-06-17 | 1999-12-23 | Akzo Nobel N.V. | Antithrombotic compounds |
| TWI289566B (en) * | 1999-12-07 | 2007-11-11 | N.V.Organon | Antithrombotic compound |
| FR2814463B1 (fr) * | 2000-09-22 | 2002-11-15 | Sanofi Synthelabo | Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine |
| EP1574516A1 (de) * | 2004-03-05 | 2005-09-14 | Sanofi-Aventis | Antithrombotische Verbindungen |
-
2006
- 2006-10-06 BR BRPI0617215-6A patent/BRPI0617215A2/pt not_active IP Right Cessation
- 2006-10-06 KR KR1020087010058A patent/KR20080055960A/ko not_active Abandoned
- 2006-10-06 EP EP06807029A patent/EP1991271B1/de active Active
- 2006-10-06 RU RU2008118365/04A patent/RU2434876C2/ru not_active IP Right Cessation
- 2006-10-06 WO PCT/EP2006/067127 patent/WO2007042469A2/en not_active Ceased
- 2006-10-06 MY MYPI20081018A patent/MY145269A/en unknown
- 2006-10-06 CA CA2624588A patent/CA2624588C/en active Active
- 2006-10-06 NZ NZ567221A patent/NZ567221A/en not_active IP Right Cessation
- 2006-10-06 JP JP2008535002A patent/JP5060486B2/ja active Active
- 2006-10-06 AU AU2006301331A patent/AU2006301331B2/en active Active
- 2006-10-06 PL PL06807029T patent/PL1991271T3/pl unknown
- 2006-10-06 HR HR20110331T patent/HRP20110331T1/hr unknown
- 2006-10-06 AT AT06807029T patent/ATE500849T1/de not_active IP Right Cessation
- 2006-10-06 DE DE602006020634T patent/DE602006020634D1/de active Active
-
2008
- 2008-03-31 IL IL190523A patent/IL190523A0/en unknown
- 2008-04-02 NO NO20081619A patent/NO20081619L/no not_active Application Discontinuation
- 2008-05-09 EC EC2008008443A patent/ECSP088443A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5060486B2 (ja) | 2012-10-31 |
| WO2007042469A3 (en) | 2007-11-29 |
| KR20080055960A (ko) | 2008-06-19 |
| RU2434876C2 (ru) | 2011-11-27 |
| WO2007042469A2 (en) | 2007-04-19 |
| NO20081619L (no) | 2008-07-03 |
| IL190523A0 (en) | 2008-11-03 |
| CA2624588C (en) | 2014-05-20 |
| JP2009511543A (ja) | 2009-03-19 |
| MY145269A (en) | 2012-01-13 |
| EP1991271A2 (de) | 2008-11-19 |
| AU2006301331B2 (en) | 2011-12-22 |
| AU2006301331A1 (en) | 2007-04-19 |
| RU2008118365A (ru) | 2009-11-20 |
| CA2624588A1 (en) | 2007-04-19 |
| NZ567221A (en) | 2010-06-25 |
| EP1991271B1 (de) | 2011-03-09 |
| HRP20110331T1 (hr) | 2011-06-30 |
| ECSP088443A (es) | 2008-06-30 |
| DE602006020634D1 (de) | 2011-04-21 |
| PL1991271T3 (pl) | 2011-08-31 |
| BRPI0617215A2 (pt) | 2011-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20081619L (no) | Antitrombotiske dobbel inhibitorer omfattende en biotin markør | |
| Wu et al. | Anticoagulant and antithrombotic evaluation of native fucosylated chondroitin sulfates and their derivatives as selective inhibitors of intrinsic factor Xase | |
| BRPI0507617A (pt) | antagonistas de receptor de quimiocina | |
| BRPI0508461A (pt) | diaminopirimidinas como antagonistas de p2x3 e p2x2/3 | |
| TW200602338A (en) | Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions | |
| PE20060078A1 (es) | Compuesto pirazolo [3,4-b]piridina como inhibidor de fosfodiesterasa tipo iv | |
| CY1114906T1 (el) | Νεα παραγωγα 6-τριαζολοπυριδαζινο-σουλφανυλο βενζοθειαζολης και βενζιμιδαζολης, η διαδικασια της παρασκευης τους, η εφαρμογη τους ως φαρμακα, φαρμακευτικες συνθεσεις και νεα χρηση κυριως ως αναστολεις του μετ | |
| BRPI0708490B8 (pt) | composto, composição farmacêutica, processo para preparar um composto da fórmula (i), e uso de um composto | |
| NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
| AR078082A1 (es) | Composiciones farmaceuticas que comprenden fucanos modificados, metodos y kits relacionados | |
| NO20090459L (no) | 18-metyl-19-nor-androst-4-en-17,17-spiroeter (18-metyl-19-nor-20-spiroks-4-en-3-on) og farmasoytiske preparater inneholdende disse | |
| UA94593C2 (ru) | Антитромбозные двойные ингибиторы с биотиновой меткой | |
| AU2008228162A1 (en) | Low molecular weight heparins including at least one covalent bond with biotin or a biotin derivative, method for making same and use thereof | |
| EA200500899A1 (ru) | Антагонисты аденозиндифосфатного рецептора тромбоцитов | |
| WO2007042470A3 (en) | Antithrombotic compound | |
| NO20072878L (no) | Antitrombotiske dobbelt inhibitorer omfattende en biotin-rest | |
| BRPI0507345A (pt) | composto antitrombótico | |
| Spickenreither et al. | Novel 6-O-acylated vitamin C derivatives as hyaluronidase inhibitors with selectivity for bacterial lyases | |
| BRPI0411867A (pt) | tiofenilaminoimidazolinas | |
| BRPI0608184A2 (pt) | composições farmacêuticas compreendendo inibidores da nep, inibidores da nep, inibidores do sistema de produção de endotelina endógena e diuréticos | |
| BR0308807A (pt) | Compostos tiazol-2-il-imina como inibidores de pde-7 | |
| WO2007064620A3 (en) | Compositions comprising a combination of ccr5 and cxcr4 antagonists | |
| BRPI0511480A (pt) | derivados de azaaçúcar, inibidores de herparanases, seu processo de preparação, as composições que os contêm, sua utilização | |
| JP2009511543A5 (de) | ||
| NL2031742B1 (en) | Pseudo-Disaccharide Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |